Review
doi: 10.1016/j.leukres.2020.106499.
Epub 2020 Dec 31.
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Affiliations
- PMID: 33422770
- DOI: 10.1016/j.leukres.2020.106499
Item in Clipboard
Review
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Leuk Res.
2021 Feb.
Free article
No abstract available
Keywords: Drug resistance; MDR1; Myeloma; Proteasome inhibitors.
Similar articles
-
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.Am J Hematol. 2013 Apr;88(4):265-72. doi: 10.1002/ajh.23387. Epub 2013 Mar 8. Am J Hematol. 2013. PMID: 23475625 Free PMC article.
-
Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.Molecules. 2019 Nov 30;24(23):4383. doi: 10.3390/molecules24234383. Molecules. 2019. PMID: 31801248 Free PMC article.
-
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.Leukemia. 2018 Feb;32(2):391-401. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5. Leukemia. 2018. PMID: 28676669 Free PMC article.
-
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.Xenobiotica. 2008 Jul;38(7-8):802-32. doi: 10.1080/00498250701867889. Xenobiotica. 2008. PMID: 18668431 Review.
-
Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.Drug Resist Updat. 2017 May;32:23-46. doi: 10.1016/j.drup.2017.10.003. Epub 2017 Oct 16. Drug Resist Updat. 2017. PMID: 29145976 Review.
Cited by
-
Cancer drug resistance in multiple myeloma.Cancer Drug Resist. 2022 Mar 25;5(2):271-276. doi: 10.20517/cdr.2022.32. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35800374 Free PMC article. No abstract available.
-
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.Leukemia. 2022 Jul;36(7):1887-1897. doi: 10.1038/s41375-022-01597-y. Epub 2022 May 28. Leukemia. 2022. PMID: 35643867 Free PMC article.
-
Identification of TNFRSF1A as a novel regulator of carfilzomib resistance in multiple myeloma.Oncol Res. 2023 Dec 28;32(2):325-337. doi: 10.32604/or.2023.030770. eCollection 2023. Oncol Res. 2023. PMID: 38186567 Free PMC article.
-
An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.Cell Death Dis. 2022 Nov 18;13(11):969. doi: 10.1038/s41419-022-05421-4. Cell Death Dis. 2022. PMID: 36400754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
